BiotechTube
Home/Pipeline/Precision DACs

Precision DACs

Undisclosed solid tumors

DiscoveryPlatform research

Key Facts

Indication
Undisclosed solid tumors
Phase
Discovery
Status
Platform research
Company
Prelude Therapeutics

About Prelude Therapeutics

Prelude Therapeutics is a publicly traded, clinical-stage biotech focused on discovering and developing targeted cancer therapies. The company has built a diverse pipeline of 11 candidates, with key programs including a selective SMARCA2 degrader (PRT3789) for SMARCA4-mutant cancers and a CDK9 inhibitor (PRT2527) for hematologic and solid tumors. Its strategy centers on applying novel mechanisms like targeted protein degradation to clinically validated targets to create differentiated, precision medicines. Prelude operates with an integrated R&D team aiming to translate scientific insights into transformative treatments for patients.

View full company profile

Therapeutic Areas

Oncology

Other Undisclosed solid tumors Drugs

DrugCompanyPhase
Macrophage-Targeting Agonist AntibodyBolt BiotherapeuticsPhase 1
IMA204Immatics BiotechnologiesPhase 1
TAR002TargImmune TherapeuticsPre-clinical
TAR003TargImmune TherapeuticsPre-clinical
ERAS-113ErascaDiscovery
Multiple ProgramsAktis OncologyDiscovery
BAT5506CompugenPreclinical
V2ACT ImmunotherapyGeneluxPhase 1
ATOR-4066Alligator Bioscience ABDiscovery/Preclinical
ACR-6840Acrivon TherapeuticsPreclinical
ADC ProgramLantern PharmaDiscovery/Preclinical
Albumin Shield™-Enabled OVTheriva BiologicsPreclinical